Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
December 02, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small...
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
November 21, 2024 18:33 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
October 16, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a...
Immuron Travelan® continued strong sales growth
October 15, 2024 06:00 ET
|
Immuron Limited
Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter...
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
October 04, 2024 06:30 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024 11:54 ET
|
Immuron Limited
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on...
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
August 16, 2024 06:00 ET
|
Immuron Limited
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16,...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
August 15, 2024 18:14 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
August 07, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be...
Immuron announces record Travelan® sales globally, Australia and USA
July 15, 2024 08:00 ET
|
Immuron Limited
Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7...